HAVCR2 and acute myeloid leukemia: Kikushige et al. analyzed 35 AML patients and observed high TIM-3 expression in CD34+CD38− and CD34+CD38+ cells in nearly all M0, M1, M2, and M4 patients, whereas M5, M6, and M7 patients showed variable expression [10].